Ventura Securities has reiterated its Buy rating and sharply raised its target price to ₹406 from its earlier target of ₹284, implying an upside potential of 41.9% over a 24-month horizon at the current market price of ₹286. The brokerage believes the company's execution has remained robust since initiating coverage, with faster-than-expected bed additions positioning Park Medi World to achieve its FY28 capacity target ahead of schedule. Healthy occupancy levels provide further headroom for both capacity expansion and margin improvement, with the company's blended ARPOB increasing from ₹26,206 to ₹30,040, supported by a richer case mix and 440 basis points YoY increase in super-speciality revenue share to 61.7%.
Ventura Securities expects the company's revenue, EBITDA and profit after tax to record compound annual growth rates of 26.8%, 28.8% and 33.4% respectively between FY26 and FY29E. By FY29E, revenue is projected to reach ₹3,420 crore, EBITDA ₹949 crore and PAT ₹631 crore. The brokerage expects EBITDA margin to improve by around 140 basis points, from 26.4% to 27.8%, while PAT margin is projected to expand by approximately 280 basis points, from 15.7% to 18.5%. The company's relatively low capital intensity is highlighted, with capex per bed at ₹37 lakh and its FY27-FY28 expansion programme budgeted at a blended ₹36 lakh per bed. As per Ventura, hospitals operating above 60% occupancy generate EBITDA margins of 30-31%, compared with 15-20% for hospitals below this level.
The board of Park Medi World at its meeting held on 31 August 2026 has approved the incorporation of a wholly-owned subsidiary as a Special Purpose Vehicle for a 550-bed multi-super-speciality hospital in Prayagraj, Uttar Pradesh. According to the company's regulatory filing with the National Stock Exchange of India (NSE), the proposed entity will operate under the name and style of Park Medicity Prayagraj Limited or Park Hospital Prayagraj Limited, subject to approval by the Ministry of Corporate Affairs. The company will subscribe to ₹0.15 crore worth of equity shares with a face value of ₹10 each, totaling ₹15 lakh to establish 100% ownership in the newly approved Prayagraj SPV. The board meeting commenced at 10:00 AM and concluded at 10:55 AM, with the company demonstrating transparency by disseminating this information on its official website.
The ₹200 crore Prayagraj hospital project has been awarded to Park Medi World under the Public-Private Partnership (PPP) model by the Prayagraj Municipal Corporation. This reimbursement structure provides significant government support, with the Prayagraj Municipal Corporation reimbursing ₹76.52 crore towards construction costs. This reimbursement de-risks approximately 38% of the capital outlay, with the remaining funding requirement estimated at ₹123.48 crore. The project will be constructed and operated under a 45-year lease arrangement, with completion targeted within 2 years of the appointed date. The strategic utilization of a dedicated SPV for the Prayagraj hospital is described as a highly credit-positive structural move that helps insulate the core balance sheet during the construction phase. The filing notes that no specific governmental approvals are required for the incorporation itself, though the broader PPP project remains subject to the terms set by the Prayagraj Municipal Corporation.
The company's expansion pipeline includes 2,680 beds planned across multiple projects, including facilities in Panchkula, Narela, Rudrapur, Gorakhpur, Mohali, Ambala, Rohtak, Palam Vihar and Zirakpur. The largest project is the 550-bed Park Hospital-Prayagraj PPP project, expected to be commissioned in January 2029. The stock ended 0.9% lower at ₹278.35 per share on BSE, having hit its 52-week low of ₹138.15 in December and its 52-week high of ₹305.25 in July 2026. The healthcare stock has lost 4% in 1 week, over 5% in 1 month but had jumped over 45% in 6 months. The company's structured approach to large-scale hospital expansion positions it as a key growth player in Indian healthcare, with the Prayagraj facility contributing significantly to the company's vision to offer state-of-the-art medical services.
